Opko Health said this week that it has expanded its collaboration with drugmaker Bristol-Myers Squibb to use its protein biomarker discovery platform to identify markers predictive of patient response to several BMS therapeutics.

The expanded collaboration will initially focus on identifying biomarkers predicting response to the rheumatoid arthritis drug abatacept, marketed by BMS as Orencia, Thomas Kodadek, professor of chemistry and cancer biology at the Scripps Research Institute and a scientific director at Opko, told ProteoMonitor this week.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.